3 September 2020 Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, today announces further investment in virus-like particle ...
Integrated, process-savvy technologies are vital to overcoming the virus-like particles purification bottleneck.
– No evidence of immune interference; initial indication of combinability achievable with company’s VLP technology – – Next steps: Icosavax plans to initiate a Phase 2 immunogenicity trial for IVX-A12 ...
Icosavax has raised a $51 million series A round to take respiratory syncytial virus (RSV) vaccine IVX-121 through phase 1b in older adults. The vaccine is built on computationally designed ...
ROCKVILLE, Md., April 29 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) reported today that its trivalent seasonal influenza virus-like-particle (VLP)-based ...
WASHINGTON—The NAB has positioned itself against another proposal for unlicensed operations in the 6 GHz, this one submitted to the FCC by Facebook, Broadcom, Cisco, Intel and Qualcomm. The new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results